Chembio Diagnostics - Stock Price History | CEMI

Historical daily share price chart and data for Chembio Diagnostics since 2020 adjusted for splits. The latest closing stock price for Chembio Diagnostics as of August 10, 2020 is 5.69.
  • The all-time high Chembio Diagnostics stock closing price was 16.00 on June 10, 2004.
  • The Chembio Diagnostics 52-week high stock price is 15.89, which is 179.3% above the current share price.
  • The Chembio Diagnostics 52-week low stock price is 2.25, which is 60.5% below the current share price.
  • The average Chembio Diagnostics stock price for the last 52 weeks is 5.99.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Chembio Diagnostics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2019 6.0100 5.6600 7.8500 3.9400 4.5600 -19.43%
2018 8.7806 8.1000 11.5000 4.9500 5.6600 -30.98%
2017 6.2502 6.6500 8.3500 5.2500 8.2000 20.59%
2016 6.7890 5.2100 9.1200 4.2800 6.8000 27.58%
2015 4.5294 3.8700 5.3400 3.5600 5.3300 36.32%
2014 3.5915 3.4000 4.7300 2.8700 3.9100 16.02%
2013 4.4190 4.7501 5.7100 3.2900 3.3700 -28.75%
2012 4.3034 3.4400 5.2599 3.2800 4.7300 40.77%
2011 3.4753 3.2800 4.5600 2.4800 3.3600 -1.18%
2010 2.1713 2.1600 3.6400 1.5200 3.4000 51.79%
2009 1.3250 0.8800 2.9600 0.6400 2.2400 154.55%
2008 1.3837 1.9200 2.4000 0.6000 0.8800 -59.26%
2007 4.6029 6.1600 7.2000 2.1600 2.1600 -67.47%
2006 5.8140 3.0400 8.2400 2.6400 6.6400 137.14%
2005 4.8378 5.7600 6.5600 2.4400 2.8000 -51.39%
2004 10.2441 9.2000 16.0000 4.8000 5.7600 0.00%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.115B $0.034B
CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $177.124B 33.24
Medtronic (MDT) Ireland $134.640B 21.87
Stryker (SYK) United States $70.344B 27.28
Boston Scientific (BSX) United States $55.768B 32.22
Lonza Group Ag (LZAGY) Switzerland $46.044B 0.00
Baxter (BAX) United States $42.068B 25.73
Terumo (TRUMY) Japan $28.809B 36.83
Zimmer Biomet Holdings (ZBH) United States $28.652B 23.78
EssilorLuxottica Societe Anonyme (ESLOY) France $28.072B 0.00
ResMed (RMD) United States $25.339B 36.80
Sunny Optical Technology (SNPTF) China $20.401B 0.00
Smith & Nephew SNATS (SNN) United Kingdom $17.905B 0.00
Bio-Rad Laboratories (BIO) United States $15.045B 68.05
Insulet (PODD) United States $13.389B 566.50
Shandong Weigao Medical Polymer (SHWGF) China $12.315B 0.00
DiaSorin S.p.A (DSRLF) Italy $11.312B 0.00
Quidel (QDEL) United States $9.636B 51.04
GN STORE NORD (GNNDY) Denmark $8.157B 41.58
William Demant Holdings (WILYY) Denmark $7.457B 0.00
Perrigo (PRGO) Ireland $7.061B 12.12
Canopy Growth (CGC) Canada $6.650B 0.00
Hill-Rom Holdings (HRC) United States $6.384B 15.84
Hutchison China MediTech (HCM) Hong Kong, SAR China $4.311B 0.00
Neogen (NEOG) United States $4.168B 69.64
Haemonetics (HAE) United States $4.002B 26.67
ICU Medical (ICUI) United States $3.727B 28.58
Envista Holdings (NVST) United States $3.647B 24.87
Abcam (ABCZY) $3.548B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.538B 0.00
Agios Pharmaceuticals (AGIO) United States $2.913B 0.00
National Vision Holdings (EYE) United States $2.828B 439.63
NuVasive (NUVA) United States $2.699B 37.62
TG Therapeutics (TGTX) United States $2.058B 0.00
DFB Healthcare Acquisitions (AHCO) United States $2.013B 185.38
AtriCure (ATRC) United States $1.896B 0.00
MacroGenics (MGNX) United States $1.504B 0.00
Aphria (APHA) Canada $1.333B 0.00
NanoString Technologies (NSTG) United States $1.322B 0.00
Aurora Cannabis (ACB) Canada $1.180B 0.00
Cerus (CERS) United States $1.172B 0.00
Omeros (OMER) United States $1.162B 0.00
Cardiovascular Systems (CSII) United States $1.092B 0.00
OraSure Technologies (OSUR) United States $1.041B 0.00
InMode (INMD) Israel $0.989B 24.94
Quanterix (QTRX) United States $0.945B 0.00
Lantheus Holdings (LNTH) United States $0.919B 12.73
Owens & Minor (OMI) United States $0.878B 19.67
PetIQ (PETQ) United States $0.877B 25.32
Phibro Animal Health (PAHC) United States $0.816B 16.26
Meridian Bioscience (VIVO) United States $0.791B 18.27
Vapotherm (VAPO) United States $0.743B 0.00
BioLife Solutions (BLFS) United States $0.721B 376.17
VAREX IMAGING (VREX) United States $0.649B 16.12
Surmodics (SRDX) United States $0.643B 70.52
Zynex (ZYXI) United States $0.628B 54.82
LeMaitre Vascular (LMAT) United States $0.602B 36.74
Eagle Pharmaceuticals (EGRX) United States $0.592B 83.19
Cytosorbents (CTSO) United States $0.407B 0.00
Viemed Healthcare (VMD) United States $0.404B 14.44
Neptune Wellness Solutions (NEPT) Canada $0.339B 0.00
HEXO (HEXO) $0.333B 0.00
Utah Medical Products (UTMD) $0.293B 25.16
InfuSystems Holdings (INFU) United States $0.270B 149.44
Organigram Holdings (OGI) Canada $0.235B 0.00
Female Health (VERU) United States $0.214B 0.00
Chimerix (CMRX) United States $0.201B 0.00
Bovie Medical (APYX) United States $0.176B 0.00
Exagen (XGN) United States $0.170B 0.00
Surface Oncology (SURF) United States $0.168B 0.00
Fonar (FONR) United States $0.168B 14.88
Wound Management Technologies (SMTI) United States $0.166B 0.00
Green Organic Dutchman Holdings (TGODF) Canada $0.133B 0.00
Liberty Health Sciences (LHSIF) Canada $0.126B 0.00
Evolus (EOLS) United States $0.125B 0.00
Rockwell Medical (RMTI) United States $0.119B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.094B 0.00
Capricor Therapeutics (CAPR) United States $0.087B 0.00
MTech Acquisition (KERN) United States $0.086B 0.00
United-Guardian (UG) United States $0.071B 15.88
Nephros (NEPH) United States $0.068B 0.00
Brainsway (BWAY) Israel $0.066B 0.00
Trinity Biotech (TRIB) Ireland $0.062B 0.00
ImmuCell (ICCC) United States $0.041B 0.00
Akers Biosciences Inc (AKER) United States $0.040B 0.00
GUARDION HEALTH (GHSI) United States $0.038B 0.00
FSD PHARMA INC (HUGE) Canada $0.026B 0.00
NF Energy Saving (BIMI) China $0.022B 0.00
Myomo (MYO) United States $0.011B 0.00
Conatus Pharmaceuticals (HSTO) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.009B 0.00
Senestech (SNES) United States $0.007B 0.00